Breast Cancer

Final results from PALLAS: adjuvant palbociclib in HR+/HER2- early breast cancer [Video]

Michael Gnant, MD, Medical University of Vienna, Vienna, Austria, shares the final results from the randomized, Phase III PALLAS trial (NCT02513394). PALLAS investigated whether the addition of the CDK4/6 inhibitor, palbociclib, to adjuvant endocrine therapy improves outcomes over endocrine therapy alone in patients with hormone receptor-positive, HER2-negative early breast cancer. The addition of palbociclib did not improve survival endpoints in this patient population; whether the addition of CDK4/6 inhibition to particular subgroups of patients is being investigated. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.